Physician profile
Peter U Baik
NPI 1003063173
$46,469.38
in general payments reported to CMS, 2019-2025
37 companies · $725 in 2025
The $725 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $9,165 · 2021: $12K · 2022: $2,819 · 2023: $290 · 2024: $2,181 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,424 · Consulting Fee: $1,050 · Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,424.27 |
| Consulting Fee | $1,050.00 |
| Food and Beverage | $721.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $39,766.85 | 2019-2024 | Imfinzi |
| Intuitive Surgical, INC. | $2,039.94 | 2019-2024 | Da Vinci Surgical System |
| Astrazeneca Uk Limited | $1,395.00 | 2021 | |
| Ethicon INC. | $719.91 | 2021 | |
| Davol INC. | $580.41 | 2025 | Progel Applicator Spray Tips |
| Merck Sharp & Dohme LLC | $253.40 | 2019-2025 | Keytruda, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $214.52 | 2019-2024 | Fruzaqla |
| Genentech USA, INC. | $182.51 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $164.63 | 2019-2020 | |
| Lilly USA, LLC | $136.26 | 2019-2020 | |
| Auris Health, INC. | $132.15 | 2019 | |
| Galvanize Therapeutics, INC | $119.93 | 2024 | Aliya System |
| Novartis Pharmaceuticals Corporation | $92.04 | 2019-2020 | |
| Amgen INC. | $64.14 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $51.36 | 2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $49.62 | 2019-2021 | |
| Celgene Corporation | $47.61 | 2019 | |
| Array Biopharma INC | $47.59 | 2019 | |
| Abbvie INC. | $36.15 | 2019-2020 | |
| Janssen Biotech, INC. | $33.00 | 2019 | |
| Eisai INC. | $30.86 | 2020 | |
| Histosonics, INC. | $28.82 | 2025 | |
| Seagen INC. | $26.49 | 2019-2020 | |
| Epizyme, INC. | $26.22 | 2020-2021 | |
| Allergan, INC. | $26.00 | 2020 | |
| Kite Pharma, INC. | $20.93 | 2019 | |
| Convatec INC. | $20.58 | 2023 | |
| Acceleron Pharma, INC. | $20.14 | 2020 | |
| Genzyme Corporation | $18.72 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $18.12 | 2024 | Exparel |
| Blueprint Medicines Corporation | $17.56 | 2021 | |
| Daiichi Sankyo INC. | $16.61 | 2020 | |
| Clovis Oncology, INC. | $15.86 | 2021 | |
| Acacia Pharma INC | $15.03 | 2021 | |
| Karyopharm Therapeutics INC. | $14.84 | 2021 | |
| Medline Industries LP | $13.63 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Baik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.